Relmada CEO buys 200,000 shares in open market

Relmada Therapeutics’ CEO reported buying 200,000 RLMD shares in open-market transactions over two days in September 2026.

Rhea-AI Filing Summary

RELMADA THERAPEUTICS, INC. (RLMD) director and Chief Executive Officer Sergio Traversa reported open-market purchases of the company’s common stock on two consecutive days. On September 9, 2026, he purchased 100,000 shares at a weighted average price of $4.18 per share, with individual trade prices ranging from $4.15 to $4.22. On September 10, 2026, he purchased an additional 100,000 shares at a weighted average price of $4.10 per share, with trade prices ranging from $4.03 to $4.11. No Rule 10b5-1 trading plan is reported for these transactions.

Insider Trade Summary

Net Buyer: 200,000 shares

Net Buy 2 txns

Insider TRAVERSA SERGIO

Role Chief Executive Officer

Bought 200,000 shs ($828K)

Type	Security	Shares	Price	Value
Purchase	Common Stock F1, F3	100,000	$4.10	$410K
Purchase	Common Stock F1, F2	100,000	$4.18	$418K

Holdings After Transaction: Common Stock — 1,500,000 shares (Direct)

Footnotes (3)

1. F1. The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.
2. F2. Purchase prices range from $4.15 to $4.22 per share, inclusive.
3. F3. Purchase prices range from $4.03 to $4.11 per share, inclusive

Key Figures

Shares purchased September 9, 2026: 100,000 shares Weighted average price September 9, 2026: $4.18 per share Shares purchased September 10, 2026: 100,000 shares +2 more

5 metrics

Shares purchased September 9, 2026 100,000 shares Open-market purchase of RLMD common stock by the CEO

Weighted average price September 9, 2026 $4.18 per share Price for 100,000-share open-market purchase; trades $4.15–$4.22

Shares purchased September 10, 2026 100,000 shares Second-day open-market purchase of RLMD common stock by the CEO

Weighted average price September 10, 2026 $4.10 per share Price for 100,000-share open-market purchase; trades $4.03–$4.11

Total shares purchased 200,000 shares Aggregate of September 9–10, 2026 open-market purchases by the CEO

Key Terms

weighted average price, open market transactions, Rule 10b5-1

3 terms

weighted average price financial

"The price reported represents the weighted average price"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open market transactions market

"shares purchased in multiple open market transactions over a range"

Open market transactions are the buying and selling of a company’s shares or other securities conducted on public exchanges or through the wider market rather than through private deals or negotiated placements. They matter to investors because these trades change supply and demand in real time—like shoppers affecting a store’s inventory—and so can move prices, signal management or investor sentiment, affect liquidity, and alter ownership stakes that influence future returns and risk.

Rule 10b5-1 regulatory

"No Rule 10b5-1 trading plan is reported for these transactions"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider activity did RLMD report in this Form 4?

The Chief Executive Officer, Sergio Traversa, reported purchasing 200,000 shares of Relmada Therapeutics common stock in open-market transactions over two days in September 2026.

How many RLMD shares did the CEO buy on September 9, 2026?

On September 9, 2026, the CEO purchased 100,000 RLMD shares of common stock at a weighted average price of $4.18 per share, with individual trades executed between $4.15 and $4.22 per share.

How many RLMD shares did the CEO buy on September 10, 2026?

On September 10, 2026, the CEO purchased 100,000 RLMD shares of common stock at a weighted average price of $4.10 per share, with trade prices ranging from $4.03 to $4.11 per share.

Were the RLMD insider purchases made under a Rule 10b5-1 trading plan?

No. The filing indicates no Rule 10b5-1 trading plan is reported for these transactions, meaning the purchases are not identified as being made under a pre-arranged trading plan.

What type of transactions did the RLMD CEO report?

The CEO reported open-market purchases of Relmada Therapeutics common stock, coded as purchase transactions, with prices reported on a weighted average basis over multiple individual trades each day.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/11/2026 - 07:30 AM Accepted by SEC EDGAR 09/11/2026 - 07:30 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

TRAVERSA SERGIO

(Last) (First) (Middle)

C/O RELMADA THERAPEUTICS, INC.

2222 PONCE DE LEON BLVD, 3RD FLOOR

(Street)

CORAL GABLES FLORIDA 33134

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
RELMADA THERAPEUTICS, INC. [ RLMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/09/2026		P		100,000(1)	A	$4.18(2)	1,400,000	D
Common Stock	09/10/2026		P		100,000(1)	A	$4.1(3)	1,500,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.

2. Purchase prices range from $4.15 to $4.22 per share, inclusive.

3. Purchase prices range from $4.03 to $4.11 per share, inclusive

	/s/ Sergio Traversa	09/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)